Preoperative Use of Tranexamic Acid to Reduce Bleeding in Adults Undergoing Major Colorectal Surgery

What this Trial Is About

Researchers are evaluating whether preoperative use of tranexamic acid TXA can reduce bleeding during and after major colorectal surgery. This phase 2 randomized clinical trial is designed to answer key questions about the effects of TXA on blood loss, bleeding complications, and the risk of blood clot-related problems within 30 days after surgery. Participants are randomly assigned to two groups one receives TXA, given as a 1 gram intravenous bolus in 100 ml saline over 10 minutes at both the start and end of surgery for a total of 2 grams, while the other group receives standard care without TXA. The study compares these approaches to see if TXA affects bleeding and clotting outcomes. During the study, researchers will monitor changes in hemoglobin levels from before surgery to the lowest level within 30 days after surgery. They will also track bleeding complications such as blood transfusions, return to surgery, or death due to bleeding, along with thromboembolic events like stroke, heart attack, deep vein thrombosis, or pulmonary embolism within 30 days. The entire study period includes follow-up to assess these outcomes and ensure patient safety.

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery